Daisy Khera

Daisy Khera

Auto-generated profile, based on publicly available information

Daisy Khera

Department of Pediatrics, All India Institute of Medical Sciences, Jodhpur, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
DKDeepthi Krishna
Deepthi Krishna
DKDaisy Khera
Daisy Khera
NTNisha Toteja
Nisha Toteja
BSBinit Sureka
Binit Sureka
BCBharat Choudhary
Bharat Choudhary
KSKuldeep Singh
Kuldeep Singh

10 December 2020 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
DKDaisy Khera
Daisy Khera
SSSurjit Singh
Surjit Singh
PPPURVI PUROHIT
PURVI PUROHIT
PSPraveen Sharma
Praveen Sharma
KSKuldeep Singh
Kuldeep Singh
Zinc deficiency,Acute respiratory infections,Zinc supplementation.

21 March 2022 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
GSGautam Sudhakar
Gautam Sudhakar
JAJitender Aneja
Jitender Aneja
PGPratibha Gehlawat
Pratibha Gehlawat
NNNaresh Nebhinani
Naresh Nebhinani
DKDaisy Khera
Daisy Khera
KSKuldeep Singh
Kuldeep Singh

20 June 2022 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
KSKuldeep Singh
Kuldeep Singh
SSSurjit Singh
Surjit Singh
PKPrawin Kumar
Prawin Kumar
DKDaisy Khera
Daisy Khera
PSPraveen Sharma
Praveen Sharma
SSSimranjeet Singh
Simranjeet Singh
Sepsis in children is a conundrum of diagnostic and therapeutic challenges. There is an exigent need for a novel biomarker that can serve as a clear distinguisher of sepsis from other non-septic inflammatory conditions. The role of presepsin as a biomarker of sepsis in children is still a matter of scientific inquiry. To evaluate the diagnostic accuracy of presepsin for the prediction of septic shock, in children aged 1 month to 18 years. This prospective cohort study was conducted in the pediatric emergency, ward, and intensive care unit of a tertiary care hospital. We enrolled all consecutive admissions aged 1 month to 18 years with a diagnosis of sepsis and compared the presepsin, procalcitonin, and C-reactive protein (CRP) levels on admission (day 1) and 72 hours later (day 4) with the clinical outcomes. The mean (±SD) presepsin values in blood culture-proven sepsis patients at admission and 72 hours later were 609.77 ± 417.30 and 839 ± 748.07, respectively. The procalcitonin and presepsin levels at 72 hours in sepsis patients with shock were significantly elevated (38.2 ± 45.55 and 1129.1 ± 1133.80, respectively) as compared to those without shock (10.7 ± 25.42 and 472.5 ± 507.81, respectively), p <0.05. The receiver operating characteristic (ROC) curve analysis of presepsin at 72 hours had an area under curve (AUC) of 0.730, suggesting a fair diagnostic accuracy. Elevated presepsin levels may indicate greater severity of sepsis, particularly in those with shock. However, it lacks diagnostic ability early in the disease and has limited prognostic potential in predicting mortality. Khera D, Toteja N, Singh S, Singh S, Kumar P, Sharma P, et al. Is There a Role of Presepsin as a Novel Biomarker in Pediatric Sepsis? Indian J Crit Care Med 2022;26(6):712–716.

14 December 2023 in Indian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
KMKeshav Mehra
Keshav Mehra
DKDaisy Khera
Daisy Khera
SDSiyaram Didel
Siyaram Didel
VTVibhor Tak
Vibhor Tak

9 August 2021 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
SSSurjit Singh
Surjit Singh
DKDaisy Khera
Daisy Khera
ACAnkita Chugh
Ankita Chugh
SKSAMEER UTTAMRAO KHASBAGE
SAMEER UTTAMRAO KHASBAGE
PKPushpinder S. Khera
Pushpinder S. Khera
VCVinay Kumar Chugh
Vinay Kumar Chugh
COVID-19 is a pandemic caused by SARS-CoV-2 virus which is a very worrisome public health emergency. In this study, we compared the mortality rate and recovery rate in countries with and without BCG vaccination policy. The data of mortality of COVID-19 was extracted from worldometer (https://www.worldometers.info/coronavirus/) on 26th July 2020. The data of countries where BCG vaccination is being done for all individuals is taken from BCG world atlas (http://www.bcgatlas.org/index.php), updated in 2017. BCG vaccination policy recommended countries are intervention group versus countries without BCG vaccination policies which are regarded as control group. Pooled analysis of countries with and without BCG vaccination policy revealed mortality rate of 1.31% (95%CI – 1.31% to 1.32%; I2 = 100%, p<0.01) and 3.25% (95%CI – 3.23% to 3.26%; I2 = 100%, p<0.01), respectively. The recovery rate in two country groups were found to be 72.60% (95%CI – 72.57% to 72.63%) and 55.94% (95%CI – 55.90% to 55.98%), respectively. 52 individuals need to be BCG vaccinated to prevent one death (NNT = 52). In BCG vaccination program countries, there is statistically and clinically significant less mortality (p-value <0.001) as compared to countries without BCG policy. Our findings corroborate the hypothesis that BCG vaccination may provide protection from COVID-19. High quality evidence from randomised controlled trials are required to establish causality between BCG vaccination and protection from severe COVID-19.